氯芐哌醚聯(lián)苯酰苯酸鹽
| 中文名稱 | 氯芐哌醚聯(lián)苯酰苯酸鹽 |
|---|---|
| 中文同義詞 | 氯芐哌醚聯(lián)苯酰苯酸鹽;氯哌斯汀芬地柞酸鹽;氯哌斯汀芬地柞酸;氯哌酮芬地唑;1-(2-((4-氯苯基)(苯基)甲氧基)乙基)哌啶 2-(6-羥基-[1,1'-聯(lián)苯]-3-羰基)苯甲酸鹽;化合物 T13619;氯芐哌醚聯(lián)苯酰苯酸鹽,10 MM DMSO 溶液;Cloperastine fendizoate氯芐哌醚聯(lián)苯酰苯酸鹽 |
| 英文名稱 | o-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]benzoic acid, compound with 1-[2-(4-chlorobenzhydryloxy)ethyl]piperidine (1:1) |
| 英文同義詞 | o-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]benzoic acid, compound with 1-[2-(4-chlorobenzhydryloxy)ethyl]piperidine (1:1);Cloperastine Febdizoate;1-[2-[(4-Chlorophenyl)phenylmethoxy]ethyl]piperidine Fendizoate;Levocloperastine Fendizoate Racemic Impurity;1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine,2-(4-hydroxy-3-phenylbenzoyl)benzoic acid;Cloperastine fendiz;o-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]benzoic acid, compound with 1-[2-(4-chlorobenzhydryloxy)ethyl]piperidine (1:1) ISO 9001:2015 REACH;o-[(2'-hydroxy[1,1'-biphenyl]-4-yl)carbonyl]benzoic acid, co... |
| CAS號(hào) | 85187-37-7 |
| 分子式 | C40H38ClNO5 |
| 分子量 | 648.2 |
| EINECS號(hào) | 286-126-9 |
| 相關(guān)類別 | 醫(yī)藥原料 |
| Mol文件 | 85187-37-7.mol |
| 結(jié)構(gòu)式 | ![]() |
氯芐哌醚聯(lián)苯酰苯酸鹽 性質(zhì)
| 熔點(diǎn) | 185-187°C |
|---|---|
| 儲(chǔ)存條件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | 可溶于DMSO(少許)、甲醇(少許) |
| 形態(tài) | 固體 |
| 顏色 | 白色至類白色 |
| 穩(wěn)定性 | 吸濕性 |
| InChIKey | PXZFKAKWSHBDCP-UHFFFAOYSA-N |
| SMILES | C(C1C=CC=CC=1)(C1C=CC(Cl)=CC=1)OCCN1CCCCC1.OC1=CC=C(C(C2C=CC=CC=2C(=O)O)=O)C=C1C1C=CC=CC=1 |
27 nM (K + currents)
Cloperastine inhibits the hERG K + currents in a concentrationdependent manner with IC 50 value of 27±3 nM. Among the antitussive agents, Cloperastine, which possesses antitussive and antiedemic activity, also relaxes the bronchial musculature. Cloperastine is a drug with a central antitussive effect, and is also endowed with an antihistaminic and papaverine-like activity similar to codeine but without its narcotic effects.
In the anesthetized guinea pigs, Cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT interval and monophasic action potential (MAP) duration without affecting PR interval or QRS width. Cloperastine hydrochloride shows relatively low acute toxicity when administered by the intraperitoneal route in rats and mice, and shows minor toxicity by the oral route when administered as Cloperastine fendizoate, the LD 50 in rats and mice for the two administration routes exceeds 1000 and 2000 mg/kg, respectively.
安全信息
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-B2179 | 氯芐哌醚聯(lián)苯酰苯酸鹽 Cloperastine fendizoate | 85187-37-7 | 500mg | 300元 |
| 2026/06/05 | HY-B2179 | 氯芐哌醚聯(lián)苯酰苯酸鹽 Cloperastine fendizoate | 85187-37-7 | 10mM * 1mLin DMSO | 330元 |
